Zealand Pharma A/S (ZEAL) 2022年年度报告「NASDAQ」.pdf

《Zealand Pharma A/S (ZEAL) 2022年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Zealand Pharma A/S (ZEAL) 2022年年度报告「NASDAQ」.pdf（118页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report 2022Company reg.no.20045078TodayAnnual General Meeting 2021#WithZealContentsManagement reviewCEO Letter Read more on page 5Other supplementary reports 2022 Corporate Social Responsibility Report Remuneration Report Corporate Governance ReportSee our pipeline Read more on page 13Follow

2、usOverviewZealand Pharma in short 4Letter from the CEO and theChairman 52022 Achievements 8Consolidated key figures 92023 Outlook and objectives 10R&D programsPeptide platform 12R&D pipeline 13Rare diseases 14Obesity 16Type 1 diabetes 18Inflammation 19Corporate mattersCorporate matters 21Corporate s

3、ocial responsibility 24Our people and culture 26Risk management and internal control 27Financial review 30Shareholder information 32Board of Directors and Corporate Management 34Consolidated financial statementsIncome statement 41Statement of comprehensive income 41Statement of financial position 42

4、Statement of cash flows 43Statement of changes in equity 43Notes 44Financial statements of the parent companyStatement of financial position 96Statement of cash flows 97Statement of changes in equity 97Notes 98Alternative performance measures for the Group(non-audited)110ReportsStatement of the Boar

5、d of Directors and Executive Management 111Independent auditors report 112Other informationCompany information 117Financial statementsZealand Pharma Annual Report 20222OverviewZealand Pharma in short 4Letter from the CEO and theChairman 52022 Achievements 8Consolidated key figures 92023 Outlook and

6、objectives 10Zealand Pharma Annual Report 202231998Find out more about Zealand Pharma in short Our mission is to change lives with next generation peptide therapeutics.Our aim to lead in rare diseases with high unmet need:Congenital Hyperinsulinism and Short Bowel Syndrometo be a key player in the f